ACBP/DBI neutralization for the experimental treatment of fatty liver disease

Acyl-CoA binding protein (ACBP), also known as diazepam-binding inhibitor (DBI), is an extracellular checkpoint of autophagy. Here, we report that patients with histologically confirmed metabolic-associated steatohepatitis (MASH) or liver fibrosis exhibit elevated levels of circulating ACBP/DBI prot...

Descripción completa

Detalles Bibliográficos
Autores: Motiño, Omar, Lambertucci, Flavia, Joseph, Adrien, Durand, Sylvère, Anagnostopoulos, Gerasimos, Li, Sijing, Carbonnier, Vincent, Nogueira-Recalde, Uxía, Montégut, Léa, Chen, Hui, Aprahamian, Fanny, Nirmalathasan, Nitharsshini, Chiara Maiuri, María, Pietrocola, Federico, Valla, Dominique, Laouénan, Cédric, Gautier, Jean-François, Castera, Laurent, Martins, Isabelle, Kroemer, Guido
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/399598
Acceso en línea:http://hdl.handle.net/10261/399598
Access Level:acceso abierto
Palabra clave:Macroautophagy
Metabolic disorders
Descripción
Sumario:Acyl-CoA binding protein (ACBP), also known as diazepam-binding inhibitor (DBI), is an extracellular checkpoint of autophagy. Here, we report that patients with histologically confirmed metabolic-associated steatohepatitis (MASH) or liver fibrosis exhibit elevated levels of circulating ACBP/DBI protein as compared to non-affected controls. Plasma ACBP/DBI strongly correlated with the NAFLD and FIB4 scores in patients, and these correlations were independent of age and body mass index. We studied the capacity of a monoclonal antibody (mAb) neutralizing mouse ACBP/DBI to combat active liver disease in several mouse models, in which steatohepatitis had been induced by four different protocols, namely, (i) methionine/choline-deficient diet, (ii) Western style diet (WD) alone, (iii) WD combined with the hepatotoxic agent CCl4, and (iv) a combination of CCl4 injections and oral ethanol challenge. Injections of anti-ACBP/DBI mAb attenuated histological, enzymological, metabolomic and transcriptomic signs of liver damage in these four models, hence halting or reducing the progression of non-alcoholic and alcoholic liver disease. Steatosis, inflammation, ballooning and fibrosis responded to ACBP/DBI inhibition at the preclinical level. Altogether, these findings support a causal role of ACBP/DBI in MASH and liver fibrosis, as well as the possibility to therapeutically target ACBP/DBI.

Similares en LA Referencia